Last reviewed · How we verify
Experimental: Tezepelumab
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine involved in type 2 inflammation and asthma pathogenesis.
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine involved in type 2 inflammation and asthma pathogenesis. Used for Moderate-to-severe asthma (including eosinophilic and allergic phenotypes), Severe asthma with oral corticosteroid dependence.
At a glance
| Generic name | Experimental: Tezepelumab |
|---|---|
| Also known as | Tezepelumab |
| Sponsor | AstraZeneca |
| Drug class | Monoclonal antibody; TSLP inhibitor |
| Target | TSLP (Thymic Stromal Lymphopoietin) |
| Modality | Biologic |
| Therapeutic area | Immunology; Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
TSLP is produced by epithelial cells and activates dendritic cells and innate lymphoid cells to promote type 2 immune responses. By neutralizing TSLP, tezepelumab reduces downstream production of type 2 cytokines (IL-4, IL-5, IL-13) and suppresses eosinophilic and allergic inflammation. This upstream mechanism of action addresses a fundamental driver of asthma across multiple phenotypes.
Approved indications
- Moderate-to-severe asthma (including eosinophilic and allergic phenotypes)
- Severe asthma with oral corticosteroid dependence
Common side effects
- Headache
- Nasopharyngitis
- Injection site reactions
- Upper respiratory tract infection
Key clinical trials
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
- Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma (PHASE3)
- Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (PHASE3)
- Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis (PHASE2)
- Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma (PHASE3)
- Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (PHASE3)
- Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |